Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2021 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH

EDISON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
November 16, 2021 08:45 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
November 10, 2021 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
November 10, 2021 07:55 ET | Source: Hepion Pharmaceuticals, Inc.

Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
October 07, 2021 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

EDISON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
September 29, 2021 09:00 ET | Source: Hepion Pharmaceuticals, Inc.

All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431

EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
September 13, 2021 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program

Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431PK-PD models successfully predict early reductions in Pro-C3 and ALTHepion’s proprietary AI-POWR™ and machine...
September 10, 2021 16:05 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION’ Clinical Trial of CRV431 in NASH

EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
July 23, 2021 16:40 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders

EDISON, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the...
July 13, 2021 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved

Safety, Tolerability and Pharmacokinetics (“PK”) Primary Endpoints MetReductions in Liver Transaminases Indicate Dose-Related Improvements in Key NASH BiomarkerConcentration-Effect Relationship...